The approach to the patient with a difficult melanocytic lesion.
暂无分享,去创建一个
[1] S. Steigen,et al. Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course , 2003, Modern Pathology.
[2] F. Pilleul,et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. , 2003, Gastroenterology.
[3] A. Sasco,et al. The epidemiology of neonatal tumours , 2003, Pediatric Surgery International.
[4] M. Arumí-Uría,et al. Grading of Atypia in Nevi: Correlation with Melanoma Risk , 2003, Modern Pathology.
[5] D. Easty,et al. Tyrosine phosphate in melanoma progression , 2003, The British journal of dermatology.
[6] B. Bastian. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer , 2003, Oncogene.
[7] I. Ellis,et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3) , 2003, Histopathology.
[8] V. Sondak,et al. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions , 2003, Cancer.
[9] D. Elder,et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. , 2002, Archives of dermatology.
[10] M. Ladanyi,et al. Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. , 2002, The Journal of molecular diagnostics : JMD.
[11] E. Foucar. Diagnostic decision-making in anatomic pathology. , 2001, American journal of clinical pathology.
[12] H. Kerl,et al. Tutorial on melanocytic lesions. , 2001, The American Journal of dermatopathology.
[13] A. Folpe,et al. Atypical and Malignant Glomus Tumors: Analysis of 52 Cases, With a Proposal for the Reclassification of Glomus Tumors , 2001, The American journal of surgical pathology.
[14] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[15] M. MedinaPérez,et al. Atypical stromal hyperplasia of the prostate (stromal proliferation of uncertain malignant potential) , 2000 .
[16] D. Pinkel,et al. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. , 2000, The American journal of pathology.
[17] C. Cockerell,et al. Sentinel lymph node biopsy as an adjunct to management of histologically difficult to diagnose melanocytic lesions: a proposal. , 2000, Journal of the American Academy of Dermatology.
[18] M. Nucci,et al. Mucinous endometrial epithelial proliferations: a morphologic spectrum of changes with diverse clinical significance. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[19] M. Mihm,et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. , 1999, Human pathology.
[20] E. Kay,et al. Identification of vertical growth phase in malignant melanoma. A study of interobserver agreement. , 1998, American journal of clinical pathology.
[21] L. Medeiros,et al. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. , 1998, American Journal of Surgical Pathology.
[22] M A Weinstock,et al. Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. , 1997, Archives of dermatology.
[23] M. Weinstock,et al. Reliability of the Histopathologic Diagnosis of Melanocytic Dysplasia , 1997 .
[24] J. Sanger,et al. Granular Cell Tumor of Uncertain Malignant Potential , 1997, Annals of plastic surgery.
[25] A Halpern,et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. , 1997, JAMA.
[26] S. Humphreys,et al. A nationwide survey of observer variation in the diagnosis of thin cutaneous malignant melanoma including the MIN terminology. CRC Melanoma Pathology Panel. , 1997, Journal of Clinical Pathology.
[27] Sobin Lh,et al. Unusual tumors of the appendix and pseudomyxoma peritonei. , 1996 .
[28] H Brenner,et al. How independent are multiple 'independent' diagnostic classifications? , 1996, Statistics in medicine.
[29] E. Farmer,et al. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. , 1996, Human pathology.
[30] E. Foucar. Debating melanocytic tumors of the skin: does an "uncertain" diagnosis signify borderline diagnostic skill? , 1995, The American Journal of dermatopathology.
[31] C. Lewis,et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. , 1994, Journal of the American Academy of Dermatology.
[32] W. Clark,et al. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 , 1993 .
[33] S. McCarthy,et al. patients with thick melanomas surviving at least 10 years: histological, cytometric and HLA analyses , 1991, Histopathology.
[34] A. Gown,et al. Antibody HMB‐45 Identifies the Cells of Blue Nevi: An Immunohistochemical Study on Paraffin Sections , 1990, The American journal of surgical pathology.
[35] H. Skelton,et al. Spindle Cell and Epithelioid Cell Nevi with Atypia and Metastasis (Malignant Spitz Nevus) , 1989, The American journal of surgical pathology.
[36] W. Clark,et al. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. , 1989, Cancer research.
[37] J. Epstein,et al. Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma , 1989, The American journal of surgical pathology.
[38] H. King,et al. Benign and Malignant Cellular Blue Nevus A Clinicopathological Study of 30 Cases , 1988, The American Journal of dermatopathology.
[39] A. Gown,et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. , 1986, The American journal of pathology.
[40] Martin F. Mihm,et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. , 2003, Seminars in surgical oncology.
[41] B. Bastian. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[42] K Davidson,et al. Early diagnosis? , 2001, The New Zealand medical journal.
[43] P. Komminoth,et al. Spitzoid malignant melanoma with lymph-node metastasis. Is a copy-number loss on chromosome 6q a marker of malignancy? , 2001, Virchows Archiv : an international journal of pathology.
[44] M. Ross,et al. Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy , 2001, Annals of Surgical Oncology.
[45] J. V. Valero Puerta,et al. [Atypical stromal hyperplasia of the prostate (stromal proliferation of uncertain malignant potential)]. , 2000, Archivos espanoles de urologia.
[46] F. Pontén,et al. Rapid increase in diagnosis of cutaneous melanoma in situ in Sweden, 1968-1992. , 1998, Cancer detection and prevention.
[47] E. Kouri,et al. Quantitative pathology in uterine smooth muscle tumours: the case for the standard histologic classification criteria. , 1997, European journal of gynaecological oncology.
[48] L. Sobin,et al. Unusual tumors of the appendix and pseudomyxoma peritonei. , 1996, Seminars in diagnostic pathology.
[49] S. Albelda,et al. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[50] D. Sackett,et al. The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.
[51] D. Silvers,et al. The small lentiginous nevus , 1985, The American Journal of dermatopathology.
[52] W. Clark,et al. Invasive malignant melanomas lacking competence for metastasis. , 1984, The American Journal of dermatopathology.